Physicochemical and pharmacokinetic evaluation of rosuvastatin loaded nanostructured lipid carriers: influence of long- and medium-chain fatty acid mixture

被引：15

作者：

Pokharkar V. ^{[1
]}

Patil-Gadhe A. ^{[1
]}

Kaur G. ^{[1
]}

机构：

[1] Department of Pharmaceutics, Poona College of Pharmacy, Bharati Vidyapeeth University, Erandwane, Pune, 411038, Maharashtra

来源：

Journal of Pharmaceutical Investigation | 2018年 / 48卷 / 4期

关键词：

Bioavailability; Fatty acids; MYS-25; Nanostructured lipid carriers; Rosuvastatin calcium;

D O I：

10.1007/s40005-017-0342-8

中图分类号：

学科分类号：

摘要：

Combination of long and medium chain lipids show different behavior in-vivo and contribute differently for bioavailability. Aim of the present study was to evaluate the effect of long chain- (LCFA) and medium-chain (MCFA) fatty acid lipids on the bioavailability of rosuvastatin from rosuvastatin loaded nanostructured lipid carrier (RNLC). Lauric acid and capryol-90™ were selected as MCFA whereas stearic acid and oleic acid were chosen as LCFA. RNLC was prepared using melt-emulsification–ultrasonication method using different combinations of MCFA and LCFA. Non-ionic, non-toxic MYS-25 was used as stabilizing agent. RNLC showed entrapment efficiency of 85–92% denoting it to be beneficial for prolonged release of drug after oral administration. Zeta potential of −26.79 mV signifies particle stability through the repulsive forces which prevents aggregation upon storage. In-vivo oral pharmacokinetic study demonstrated six to ninefold improvement in the bioavailability of rosuvastatin (RSVS) in the form of RNLC than RSVS-Aqueous dispersion. A 1.5-fold increase in bioavailability was observed when RNLC was prepared with LCFA solid lipid and MCFA liquid lipid combination as compared to RNLC prepared using only MCFA as both solid and liquid lipid. Use of LCFA and MCFA combination was found to be superior as lipid mixture for the RNLC. © 2017, The Korean Society of Pharmaceutical Sciences and Technology.

引用

页码：465 / 476

页数：11

共 45 条

[1]

Chakraborty S., Shukla D., Mishra B., Singh S., Lipid—an emerging platform for oral delivery of drugs with poor bioavailability, Eur J Pharm Biopharm, 73, pp. 1-15, (2009)

[2]

Chen C.C., Tsai T.H., Huang Z.R., Fang J.Y., Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics, Eur J Pharm Biopharm, 74, pp. 474-482, (2010)

[3]

Chormale S.B., Vavia P.R., Development and evaluation of stable solid self-micro emulsifying drug delivery system of rosuvastatin, IPC 64Th 2012, (2012)

[4]

Chougule M., Padhi, Misra A., Nano-liposomal dry powder inhaler of tacrolimus: preparation, characterization, and pulmonary pharmacokinetics, Int J Nanomed, 2, pp. 675-688, (2007)

[5]

Clark A.M., Jepson M.A., Hirst B.H., Exploiting M cells for drug and vaccine delivery, Adv Drug Deliv Rev, 50, pp. 81-106, (2001)

[6]

Costa P., Lobo J.M.S., Modeling and comparison of dissolution profiles, Eur J Pharm Sci, 13, pp. 123-133, (2001)

[7]

Devani M., Ashford M., Craig D.Q., The emulsification and solubilisation properties of polyglycolysed oils in self-emulsifying formulations, J Pharm Pharmacol, 56, pp. 307-316, (2004)

[8]

Gershanik T., Benita S., Self-dispersing lipid formulations for improving oral absorption of lipophillic drugs, Eur J Pharm Biopharm, 50, pp. 179-188, (2000)

[9]

Grove M., Mullertz A., Nielsen J.L., Pedersen G.P., Bioavailability of seocalcitol II: development and characterization of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides, Eur J Pharm Sci, 28, pp. 233-242, (2006)

[10]

Hac-Wydro K., Wydro P., The influence of fatty acids on model cholesterol/phospholipid membranes, Chem Phys Lipids, 150, pp. 66-81, (2007)

← 1 2 3 4 5 →